On October 29, 2025, Bio-Rad Laboratories reported third-quarter earnings with sales of US$653 million and a net loss of US$341.9 million, while also completing a major share repurchase and announcing ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new Droplet Digital™ PCR (ddPCR™) ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that in two studies ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced today that the company’s management will host an informational ...

Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of an RT-PCR kit that allows researchers to simultaneously screen samples for Zika (ZIKV), dengue (DENV1, DENV2, DENV3, DENV4 ...

The SARS-CoV-2 Droplet Digital PCR (ddPCR) test runs on Bio-Rad's QX200 and QXDx ddPCR systems. The high sensitivity of the test makes it well suited to screening upper respiratory samples in patients ...

Are you new to quantitative (or “real-time”) PCR? Maybe you’re just looking to brush up on the basics of designing and analyzing qPCR experiments. Perhaps your reactions aren’t working. Again.

Q3 2025 Management View Jonathan DiVincenzo, President & COO, reported that "revenue was consistent with our outlook and operating margin exceeded consensus, a testament to the discipline and agility ...

Source: Bio-Rad Laboratories, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to ...